TAFRO syndrome successfully treated with tocilizumab: A case report and systematic review

References

• Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma. Cancer 1956;9(4): 822–30.
   PubMed Web of Science ®Google Scholar
• Fajgenbaum DC, van Rhee F, Nabel CS. HHV-8-negative, idiopathic multicentric Castleman disease: novel insights into biology, pathogenesis, and therapy. Blood 2014;123(19):2924–33.
   PubMed Web of Science ®Google Scholar
• Takai K, Nikkuni K, Shibuya H, Hashidate H. [Thrombocytopenia with mild bone marrow fibrosis accompanied by fever, pleural effusion, ascites and hepatosplenomegaly]. Rinsho Ketsueki. 2010;51(5):320–5.
   PubMedGoogle Scholar
• Kawabata H, Takai K, Kojima M, Nakamura N, Aoki S, Nakamura S, et al. Castleman-Kojima disease (TAFRO syndrome): a novel systemic inflammatory disease characterized by a constellation of symptoms, namely, thrombocytopenia, ascites (anasarca), microcytic anemia, myelofibrosis, renal dysfunction, and organomegaly: a status report and summary of Fukushima (6 June, 2012) and Nagoya meetings (22 September, 2012). J Clin Exp Hematop. 2013;53(1):57–61.
   PubMedGoogle Scholar
• Inoue M, Ankou M, Hua J, Iwaki Y, Hagihara M, Ota Y. Complete resolution of TAFRO syndrome (thrombocytopenia, anasarca, fever, reticulin fibrosis and organomegaly) after immunosuppressive therapies using corticosteroids and cyclosporin A: a case report. J Clin Exp Hematop. 2013;53(1):95–9.
   PubMedGoogle Scholar
• Kubokawa I, Yachie A, Hayakawa A, Hirase S, Yamamoto N, Mori T, et al. The first report of adolescent TAFRO syndrome, a unique clinicopathologic variant of multicentric Castleman's disease. BMC Pediatr. 2014;14:139.
   PubMed Web of Science ®Google Scholar
• Kawabata H, Kotani S, Matsumura Y, Kondo T, Katsurada T, Haga H, et al. Successful treatment of a patient with multicentric Castleman's disease who presented with thrombocytopenia, ascites, renal failure and myelofibrosis using tocilizumab, an anti-interleukin-6 receptor antibody. Intern Med. 2013;52(13):1503–7.
   PubMed Web of Science ®Google Scholar
• Suda T, Katano H, Delsol G, Kakiuchi C, Nakamura T, Shiota M, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int. 2001;51(9):671–9.
   PubMed Web of Science ®Google Scholar
• Kojima M, Nakamura N, Otuski Y, Itoh H, Ogawa Y, Kobayashi H, et al. Pulmonary lesion of idiopathic plasmacytic lymphadenopathy with polyclonal hyperimmunoglobulinemia appears to be a cause of lymphoplasmacytic proliferation of the lung: a report of five cases. Pathol Res Pract. 2008;204(3):185–90.
   PubMed Web of Science ®Google Scholar
• Kojima M, Nakamura S, Shimizu K, Itoh H, Yamane Y, Murayama K, et al. Clinical implication of idiopathic plasmacytic lymphadenopathy with polyclonal hypergammaglobulinemia: a report of 16 cases. Int J Surg Pathol. 2004;12(1):25–30.
   PubMed Web of Science ®Google Scholar
• Frizzera G. Castleman's disease and related disorders. Semin Diagn Pathol. 1988;5(4):346–64.
   PubMed Web of Science ®Google Scholar
• Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis. 2010;69(1):88–96.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Kanakura Y, Aozasa K, Johkoh T, Nakamura M, Nakano S, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005;106(8): 2627–32.
   PubMed Web of Science ®Google Scholar
• Iwaki N, Sato Y, Takata K, Kondo E, Ohno K, Takeuchi M, et al. Atypical hyaline vascular-type Castleman's disease with thrombocytopenia, anasarca, fever, and systemic lymphadenopathy. J Clin Exp Hematop. 2013;53(1):87–93.
   PubMedGoogle Scholar
• Tedesco S, Postacchini L, Manfredi L, Goteri G, Luchetti MM, Festa A, et al. Successful treatment of a Caucasian case of multifocal Castleman's disease with TAFRO syndrome with a pathophysiology targeted therapy – a case report. Exp Hematol Oncol. 2015;4(1):3.
   PubMed Web of Science ®Google Scholar
• Konishi Y, Takahashi S, Nishi K, Sakamaki T, Mitani S, Kaneko H, et al. Successful treatment of TAFRO syndrome, a variant of multicentric Castleman's disease, with cyclosporine A: possible pathogenetic contribution of interleukin-2. Tohoku J Exp Med. 2015;236(4):289–95.
   PubMed Web of Science ®Google Scholar
• Tatekawa S, Umemura K, Fukuyama R, Kohno A, Taniwaki M, Kuroda J, et al. Thalidomide for tocilizumab-resistant ascites with TAFRO syndrome. Clin Case Rep. 2015;3(6):472–8.
   PubMed Web of Science ®Google Scholar
• Awano N, Inomata M, Sonoda Y, Kondoh K, Ono R, Moriya A, et al. A case of multicentric Castleman's disease of mixed-type, which showed constellation of symptoms, i.e., thrombocytopenia, anasarca, anemia, fever, myelofibrosis, and lymphadenopathy. J Clin Exp Hematop. 2013;53(1):101–5.
   PubMedGoogle Scholar
• Ishii N, Okuno T, Fukushima H, Inoue T. Pathological diagnosis of TAFRO syndrome: a case report. Jpn J Diagn Pathol. 2015;31(4): 354–60.
   Google Scholar
• Nagai T, Maemori M, Ando S, Naganuma T, Noguchi A, Sakai M. A case of TAFRO syndrome that was refractory to tocilizumab and successfully treated with rituximab. Jpn J Clin Hematol. 2015; 56(1):62.
   Google Scholar
• Hamasaki T, Mizumoto T, Mochinaga H, Fujiwara S, Saneyoshi T, Nishi K, et al. A case of TAFRO syndrome that was successfully treated with tocilizumab and was weaned off from hemodialysis which was initiated for acute kidney injury. J Jpn Soc Dial Ther. 2015;48(Suppl. 1):801.
   Google Scholar
• Kondo H, Sato Y, Asano G, Hanayama Y, Kimura K, Tsukahara K, et al. A case of muticentric Castleman disease (MCD)/TAFRO syndrome that required intensive medical care. J Jap Soc Lymphoretic Tissue Res. 2015;55:115.
   Google Scholar
• Curciarello J, Castelletto R, Barbero R, Belloni P, Gelemur M, Castelletto E, et al. Hepatic sinusoidal dilatation associated to giant lymph node hyperplasia (Castleman's): a new case in a patient with periorbital xanthelasmas and history of celiac disease. J Clin Gastroenterol. 1998;27(1):76–8.
   PubMed Web of Science ®Google Scholar